Freshworks Announces $400 Million Stock Buyback Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy FRSH?
Source: seekingalpha
- Stock Buyback Program: Freshworks has announced a stock repurchase program of up to $400 million for its Class A common stock, aimed at enhancing shareholder value and boosting market confidence, which is expected to have a positive impact on the stock price.
- Positive Market Reaction: Following the announcement, Freshworks' stock rose 4.94% in premarket trading to $7.64 per share, indicating investor optimism regarding the company's future growth potential.
- Clear Growth Targets: Freshworks has set a target to achieve $1.3 billion in annual recurring revenue (ARR) by 2028, demonstrating its strategic focus on sustained growth through its EX platform and AI initiatives.
- Industry Context Analysis: Despite facing downgrades from Jefferies and concerns over AI, Freshworks showcases resilience and long-term growth potential in the SaaS market through its buyback program and ambitious growth targets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FRSH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FRSH
Wall Street analysts forecast FRSH stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 7.960
Low
13.00
Averages
18.88
High
25.00
Current: 7.960
Low
13.00
Averages
18.88
High
25.00
About FRSH
Freshworks Inc. is a software company. Its software-as-a-service (SaaS) solutions fall into two product families: Customer Experience (CX) and Employee Experience (EX). CX products include Freshdesk, Freshchat, Freshsales, and Freshmarketer. EX products include Freshservice, Freshservice for Business Teams, and Device42. The Company's generative artificial intelligence (AI) solutions, Freddy AI Agent and Freddy AI Copilot, further enhance the customer and employee experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Freshworks Announces $400 Million Stock Buyback Program
- Stock Buyback Program: Freshworks has announced a stock repurchase program of up to $400 million for its Class A common stock, aimed at enhancing shareholder value and boosting market confidence, which is expected to have a positive impact on the stock price.
- Positive Market Reaction: Following the announcement, Freshworks' stock rose 4.94% in premarket trading to $7.64 per share, indicating investor optimism regarding the company's future growth potential.
- Clear Growth Targets: Freshworks has set a target to achieve $1.3 billion in annual recurring revenue (ARR) by 2028, demonstrating its strategic focus on sustained growth through its EX platform and AI initiatives.
- Industry Context Analysis: Despite facing downgrades from Jefferies and concerns over AI, Freshworks showcases resilience and long-term growth potential in the SaaS market through its buyback program and ambitious growth targets.
See More
Software Earnings Are Here: A Pivotal Moment for the Industry.
- Software Earnings: Several companies are reporting their software earnings this week, which is significant for the industry.
- Sector Challenges: The software sector has faced difficulties recently, largely due to rising concerns surrounding artificial intelligence.
- Market Impact: The earnings reports may influence market perceptions and investor confidence in the software industry.
- Future Outlook: The results could provide insights into how companies are adapting to the challenges posed by AI advancements.
See More
Freshworks Stock Downgraded to Hold Amid Bearish Outlook
- Analyst Downgrade: Jefferies downgraded Freshworks stock from Buy to Hold and slashed its price target from $20 to $8, reflecting concerns over competitive pressures and risks from artificial intelligence, which may lead to decreased investor confidence.
- Weak Stock Performance: As of 1:51 p.m. ET, Freshworks shares are down 7.3%, currently priced at $6.87 with a market cap of $2.1 billion, indicating a bearish outlook from the market regarding the company's future performance.
- Follow-Up Downgrades: Following Jefferies, UBS and Baird have also reduced their price targets to $11 and $10 respectively, suggesting a cautious sentiment towards Freshworks that could influence investor decisions moving forward.
- Financial Performance Highlights: Despite the pressures, Freshworks achieved a 16% year-over-year revenue growth and a 46% increase in adjusted free cash flow in 2025, indicating that the company still possesses growth potential, prompting investors to remain patient and observe future performance.
See More
Financial Stocks Plummet While ImmunityBio Soars
- Financial Sector Decline: The financial sector of the S&P 500 fell over 3% during midday trading, with KKR and Blackstone dropping approximately 9% and 7% respectively, indicating investor concerns over alternative asset management and its potential impact on market confidence.
- Cybersecurity Stocks Volatility: The Global X Cybersecurity ETF (BUG) tumbled 4% amid anxiety over artificial intelligence, with CrowdStrike and Zscaler each falling 10%, reflecting market sensitivity to security risks posed by emerging technologies.
- ImmunityBio's Strong Growth: ImmunityBio reported a staggering 700% year-over-year revenue growth and expanded Anktiva approvals for lung cancer, leading to a 12% stock increase, showcasing its strong market potential in the clinical-stage immunotherapy sector.
- Arcellx Acquisition Surge: Gilead Sciences agreed to acquire Arcellx for $7.8 billion, resulting in a 78% stock surge, with the deal expected to close in the second quarter, marking a significant merger activity in the biotech sector.
See More
Market Dynamics and Investment Strategy Analysis
- Tariff Policy Impact: President Trump raised the global baseline tariff rate from 10% to 15%, which is likely to lead to a down open on Wall Street, potentially affecting investor confidence and exacerbating trade tensions.
- Pharmaceutical Competition: Eli Lilly triumphed over Novo Nordisk in a head-to-head trial, with Novo's obesity drug CagriSema proving less effective than Lilly's Zepbound, resulting in a 15% drop in Novo's shares while Lilly's rose over 3%, indicating increased market confidence in Lilly.
- Banking Sector Upgrade: RBC Capital Markets upgraded Spain's Banco Santander from hold to buy, anticipating that its expansion in the U.S. and upcoming investor day will enhance its market valuation, showcasing its competitive edge in the European banking sector.
- Software Industry Risks: Jefferies downgraded several software companies, citing heightened AI risks and negative sentiment, particularly impacting Workday and DocuSign, indicating a shift in market confidence towards companies like Salesforce that can disrupt themselves.
See More
U.S. Stock Futures Decline, Novo Nordisk Shares Drop
- Futures Decline: U.S. stock futures are lower this morning, with Dow futures falling approximately 100 points, indicating a cautious market sentiment that may lead investors to adopt more conservative strategies in the short term.
- Novo Nordisk Stock Drop: Novo Nordisk shares fell 8% to $43.60 in pre-market trading, reflecting market concerns about the company's future performance, which could impact investor confidence in the pharmaceutical sector.
- Market Sentiment Weakens: The overall market sentiment is influenced by multiple factors, including uncertainties in economic data and investor concerns regarding future interest rate policies, potentially leading to downward pressure on more stocks in the near term.
- Investor Strategy Adjustment: As stock futures decline, investors may reassess their portfolios and shift towards more stable asset allocations to mitigate potential market volatility.
See More
Freshworks Announces $400 Million Stock Buyback Program
- Stock Buyback Program: Freshworks has announced a stock repurchase program of up to $400 million for its Class A common stock, aimed at enhancing shareholder value and boosting market confidence, which is expected to have a positive impact on the stock price.
- Positive Market Reaction: Following the announcement, Freshworks' stock rose 4.94% in premarket trading to $7.64 per share, indicating investor optimism regarding the company's future growth potential.
- Clear Growth Targets: Freshworks has set a target to achieve $1.3 billion in annual recurring revenue (ARR) by 2028, demonstrating its strategic focus on sustained growth through its EX platform and AI initiatives.
- Industry Context Analysis: Despite facing downgrades from Jefferies and concerns over AI, Freshworks showcases resilience and long-term growth potential in the SaaS market through its buyback program and ambitious growth targets.
See More
Software Earnings Are Here: A Pivotal Moment for the Industry.
- Software Earnings: Several companies are reporting their software earnings this week, which is significant for the industry.
- Sector Challenges: The software sector has faced difficulties recently, largely due to rising concerns surrounding artificial intelligence.
- Market Impact: The earnings reports may influence market perceptions and investor confidence in the software industry.
- Future Outlook: The results could provide insights into how companies are adapting to the challenges posed by AI advancements.
See More
Freshworks Stock Downgraded to Hold Amid Bearish Outlook
- Analyst Downgrade: Jefferies downgraded Freshworks stock from Buy to Hold and slashed its price target from $20 to $8, reflecting concerns over competitive pressures and risks from artificial intelligence, which may lead to decreased investor confidence.
- Weak Stock Performance: As of 1:51 p.m. ET, Freshworks shares are down 7.3%, currently priced at $6.87 with a market cap of $2.1 billion, indicating a bearish outlook from the market regarding the company's future performance.
- Follow-Up Downgrades: Following Jefferies, UBS and Baird have also reduced their price targets to $11 and $10 respectively, suggesting a cautious sentiment towards Freshworks that could influence investor decisions moving forward.
- Financial Performance Highlights: Despite the pressures, Freshworks achieved a 16% year-over-year revenue growth and a 46% increase in adjusted free cash flow in 2025, indicating that the company still possesses growth potential, prompting investors to remain patient and observe future performance.
See More
Financial Stocks Plummet While ImmunityBio Soars
- Financial Sector Decline: The financial sector of the S&P 500 fell over 3% during midday trading, with KKR and Blackstone dropping approximately 9% and 7% respectively, indicating investor concerns over alternative asset management and its potential impact on market confidence.
- Cybersecurity Stocks Volatility: The Global X Cybersecurity ETF (BUG) tumbled 4% amid anxiety over artificial intelligence, with CrowdStrike and Zscaler each falling 10%, reflecting market sensitivity to security risks posed by emerging technologies.
- ImmunityBio's Strong Growth: ImmunityBio reported a staggering 700% year-over-year revenue growth and expanded Anktiva approvals for lung cancer, leading to a 12% stock increase, showcasing its strong market potential in the clinical-stage immunotherapy sector.
- Arcellx Acquisition Surge: Gilead Sciences agreed to acquire Arcellx for $7.8 billion, resulting in a 78% stock surge, with the deal expected to close in the second quarter, marking a significant merger activity in the biotech sector.
See More
Market Dynamics and Investment Strategy Analysis
- Tariff Policy Impact: President Trump raised the global baseline tariff rate from 10% to 15%, which is likely to lead to a down open on Wall Street, potentially affecting investor confidence and exacerbating trade tensions.
- Pharmaceutical Competition: Eli Lilly triumphed over Novo Nordisk in a head-to-head trial, with Novo's obesity drug CagriSema proving less effective than Lilly's Zepbound, resulting in a 15% drop in Novo's shares while Lilly's rose over 3%, indicating increased market confidence in Lilly.
- Banking Sector Upgrade: RBC Capital Markets upgraded Spain's Banco Santander from hold to buy, anticipating that its expansion in the U.S. and upcoming investor day will enhance its market valuation, showcasing its competitive edge in the European banking sector.
- Software Industry Risks: Jefferies downgraded several software companies, citing heightened AI risks and negative sentiment, particularly impacting Workday and DocuSign, indicating a shift in market confidence towards companies like Salesforce that can disrupt themselves.
See More
U.S. Stock Futures Decline, Novo Nordisk Shares Drop
- Futures Decline: U.S. stock futures are lower this morning, with Dow futures falling approximately 100 points, indicating a cautious market sentiment that may lead investors to adopt more conservative strategies in the short term.
- Novo Nordisk Stock Drop: Novo Nordisk shares fell 8% to $43.60 in pre-market trading, reflecting market concerns about the company's future performance, which could impact investor confidence in the pharmaceutical sector.
- Market Sentiment Weakens: The overall market sentiment is influenced by multiple factors, including uncertainties in economic data and investor concerns regarding future interest rate policies, potentially leading to downward pressure on more stocks in the near term.
- Investor Strategy Adjustment: As stock futures decline, investors may reassess their portfolios and shift towards more stable asset allocations to mitigate potential market volatility.
See More
